TP53 and neoplasm: ZS17 activates the ROS-JNK-p53 pathway, inhibits mitochondrial oxidative phosphorylation, induces apoptosis, and may further lead to mitochondrial dysfunction in tumour cells by inhibiting ATP production by HCC cells.